Xeris Biopharma Chairman and CEO Paul Edick joins Natalie Stoberman from the Proactive newsroom to share new plans for a Phase II dose-finding study for hypothyroidism, along with details of its new collaboration with Horizon Therapeutics.
Xeris is a growth-oriented biopharmaceutical company committed to improving patients’ lives by developing and commercializing innovative products across a range of therapies. Xeris has three commercially available products; Gvoke®, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia, Keveyis®, the first and only FDA-approved therapy for primary periodic paralysis, and Recorlev® for the treatment of endogenous Cushing’s syndrome.